- Home
- CRGX vs ECX Comparison
CRGX vs ECX Comparison
Compare CRGX & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- ECX
- Stock Information
- Founded
- CRGX 2021
- ECX 2017
- Country
- CRGX United States
- ECX China
- Employees
- CRGX N/A
- ECX N/A
- Industry
- CRGX
- ECX EDP Services
- Sector
- CRGX
- ECX Technology
- Exchange
- CRGX Nasdaq
- ECX Nasdaq
- Market Cap
- CRGX 190.0M
- ECX 589.5M
- IPO Year
- CRGX 2023
- ECX N/A
- Fundamental
- Price
- CRGX $4.59
- ECX $2.25
- Analyst Decision
- CRGX Hold
- ECX Strong Buy
- Analyst Count
- CRGX 7
- ECX 1
- Target Price
- CRGX $5.33
- ECX $3.20
- AVG Volume (30 Days)
- CRGX 1.9M
- ECX 3.5M
- Earning Date
- CRGX 08-11-2025
- ECX 08-07-2025
- Dividend Yield
- CRGX N/A
- ECX N/A
- EPS Growth
- CRGX N/A
- ECX N/A
- EPS
- CRGX N/A
- ECX N/A
- Revenue
- CRGX N/A
- ECX $805,604,079.00
- Revenue This Year
- CRGX $57.81
- ECX $26.72
- Revenue Next Year
- CRGX N/A
- ECX $30.34
- P/E Ratio
- CRGX N/A
- ECX N/A
- Revenue Growth
- CRGX N/A
- ECX 19.98
- 52 Week Low
- CRGX $3.00
- ECX $0.76
- 52 Week High
- CRGX $25.45
- ECX $3.25
- Technical
- Relative Strength Index (RSI)
- CRGX 61.56
- ECX 65.11
- Support Level
- CRGX $4.32
- ECX $2.01
- Resistance Level
- CRGX $4.63
- ECX $2.29
- Average True Range (ATR)
- CRGX 0.16
- ECX 0.17
- MACD
- CRGX 0.04
- ECX 0.01
- Stochastic Oscillator
- CRGX 76.44
- ECX 76.36
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.